

Small noncoding differentially methylated copy-number variants, including lncRNA genes, cause a lethal lung developmental disorder

Przemyslaw Szafranski,¹ Avinash V. Dharmadhikari,^{1,2} Erwin Brosens,^{3,4} Priyatansh Gurha,^{1,5} Katarzyna E. Kołodziejska,¹ Ou Zhishuo,¹ Piotr Dittwald,^{1,6,7} Tadeusz Majewski,⁸ K. Naga Mohan,^{1,9} Bo Chen,¹ Richard E. Person,¹ Dick Tibboel,⁴ Annelies de Klein,³ Jason Pinner,¹⁰ Maya Chopra,¹⁰ Girvan Malcolm,¹¹ Gregory Peters,¹² Susan Arbuckle,¹³ Sixto F. Guiang III,¹⁴ Virginia A. Husted,¹⁵ Jose Jessurun,¹⁶ Russel Hirsch,¹⁷ David P. Witte,¹⁷ Isabelle Maystadt,¹⁸ Neil Sebire,¹⁹ Richard Fisher,²⁰ Claire Langston,²¹ Partha Sen,²² and Paweł Stankiewicz^{1,2,23}

¹Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas 77030, USA; ²Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, Texas 77030, USA; ³Clinical Genetics Department, Erasmus MC-Sophia, 3000 CA, Rotterdam, Netherlands; ⁴Paediatric Surgery, Erasmus MC-Sophia, 3015 GJ, Rotterdam, Netherlands; ⁵Center for Cardiovascular Genetics, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center and Texas Heart Institute, Houston, Texas 77030, USA; ⁶Institute of Informatics, University of Warsaw, 02-097, Warsaw, Poland; ⁷College of Inter-Faculty Individual Studies in Mathematics and Natural Sciences, University of Warsaw, 02-089, Warsaw, Poland; ⁸Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA; ⁹Department of Biological Sciences, Birla Institute of Technology and Science-Pilani, Hyderabad-500 078, AP, India; ¹⁰Department of Molecular and Clinical Genetics, Royal Prince Alfred Hospital, Sydney, NSW 2050, Australia; ¹¹Obstetrics, Gynaecology and Neonatology, Royal Prince Alfred Hospital, Sydney, NSW 2006, Australia; ¹²Cytogenetics Department, The Children's Hospital at Westmead, Westmead, NSW 2145, Australia; ¹³Histopathology Department, The Children's Hospital at Westmead, Westmead, NSW 2145, Australia; ¹⁴Department of Pediatrics–Neonatology, University of Minnesota Medical Center, Minneapolis, Minnesota 55454, USA; ¹⁵Minnesota Neonatal Physicians, Minneapolis, Minnesota 55404, USA; ¹⁶Laboratory Medicine and Pathology, Department of Medicine, University of Minnesota Medical Center, Minneapolis, Minnesota 55454, USA; ¹⁷Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229, USA; ¹⁸Institut de Pathologie et de Génétique, B-6041 Gosselies, Belgium; ¹⁹Department of Paediatric Histopathology, Great Ormond Street Hospital for Children and UCL Institute of Child Health, London WC1N 3JH, United Kingdom; ²⁰James Cook University Hospital, Middlesbrough TS4 3BW, United Kingdom; ²¹Department of Pathology, Baylor College of Medicine, and Pulmonary Pathology, Texas Children's Hospital, Houston, Texas 77030, USA; ²²Department of Pediatrics–Neonatology, Baylor College of Medicine, Houston, Texas 77030, USA

An unanticipated and tremendous amount of the noncoding sequence of the human genome is transcribed. Long noncoding RNAs (lncRNAs) constitute a significant fraction of non-protein-coding transcripts; however, their functions remain enigmatic. We demonstrate that deletions of a small noncoding differentially methylated region at 16q24.1, including lncRNA genes, cause a lethal lung developmental disorder, alveolar capillary dysplasia with misalignment of pulmonary veins (ACD/MPV), with parent-of-origin effects. We identify overlapping deletions 250 kb upstream of *FOXF1* in nine patients with ACD/MPV that arose de novo specifically on the maternally inherited chromosome and delete lung-specific lncRNA genes. These deletions define a distant *cis*-regulatory region that harbors, besides lncRNA genes, also a differentially methylated CpG island, binds *GLI2* depending on the methylation status of this CpG island, and physically interacts with and up-regulates the *FOXF1* promoter. We suggest that lung-transcribed 16q24.1 lncRNAs may contribute to long-range regulation of *FOXF1* by *GLI2* and other transcription factors. Perturbation of lncRNA-mediated chromatin interactions may, in general, be responsible for position effect phenomena and potentially cause many disorders of human development.

[Supplemental material is available for this article.]

Mammalian regulatory elements, including enhancers, repressors, and insulators, are usually contained in genomic regions that lack

protein-coding genes and can be located hundreds of kilobases from genes that they regulate (Birney et al. 2007). High-throughput analysis of the human transcriptome revealed that the majority of the noncoding portion of the genome is transcribed as regulatory RNAs (Khalil et al. 2009; Mattick 2010). Long noncoding RNAs (lncRNAs) are non-protein-coding transcripts longer than 200 nt, distinguished from small regulatory RNAs such as microRNAs, siRNAs, piRNAs,

²³Corresponding author
E-mail pawels@bcm.edu

Article published online before print. Article, supplemental material, and publication date are at <http://www.genome.org/cgi/doi/10.1101/gr.141887.112>.

and snoRNAs. Little is known about the function of lncRNAs in humans with *XIST* being the earliest identified and best characterized to date human lncRNA. Recently, lncRNAs have been implicated in imprinting and long-range gene regulation with functional properties of enhancers (Khalil et al. 2009; Mattick 2010; Wang and Chang 2011). Here, we demonstrate that loss of a distant enhancer region in a protein-coding gene desert at 16q24.1, which includes lung-expressed lncRNA genes, leads to alveolar capillary dysplasia with misalignment of pulmonary veins (ACD/MPV; MIM 265380).

ACD/MPV is a rare, neonatally lethal developmental disorder of the lungs defined by malposition of pulmonary veins adjacent to small pulmonary arteries, medial thickening of small pulmonary arteries, deficient lobular development, a paucity of alveolar wall capillaries, and occasional lymphangiectasis (Langston 1991; Bishop et al. 2011). A few familial ACD/MPV cases have been described (Sen et al. 2004, 2012; Eulmesekian et al. 2005). During the last 10 years, we ascertained ACD/MPV samples (mainly formalin-fixed paraffin-embedded lung tissues) from more than 90 families. In 2009, we reported genomic deletions and inactivating point mutations in the *FOXF1* gene in chromosome 16q24.1 in unrelated patients with sporadic histopathologically verified ACD/MPV (Stankiewicz et al. 2009).

FOXF1 (Forkhead box protein F1) is a member of the FOX transcription factor family sharing a winged helix/forkhead DNA-binding domain (Lai et al. 1993; Pierrou et al. 1994; Kaestner et al. 2000). *FOXF1* and its mouse ortholog are predominantly expressed in subepithelial mesenchymal tissues of developing lung and foregut (Chang and Ho 2001; Mahlapuu et al. 2001a; Maeda et al. 2007; Bozyk et al. 2011). Homozygous mice deficient for *Foxf1* die in utero by embryonic day 10 (E10) due to defects in mesodermal differentiation and cell adhesion (Mahlapuu et al. 2001b). Interestingly, ~50% of *Foxf1*^{+/-} mice died from pulmonary hemorrhage and showed severe defects in alveolarization and vasculogenesis (Kalinichenko et al. 2001), partially recapitulating histopathological pulmonary defects in infants with ACD/MPV, whereas the remainder appeared normal.

Both in vitro and in vivo studies in mice have shown that none of the in silico-predicted transcription factor binding sites located within the *Foxf1* promoter confer its tissue specificity (Chang and Ho 2001; Kim et al. 2005), suggesting that the promoter is regulated by tissue-specific distant regulatory elements. Also, deletions upstream of *FOXF1*, leaving *FOXF1* intact, have been described in two patients with ACD/MPV, suggesting the presence of distant regulatory elements for *FOXF1* (Stankiewicz et al. 2009). In addition, *FOXF1* has been bioinformatically predicted to be paternally imprinted (Luedi et al. 2007), and other studies have supported this prediction (Stankiewicz et al. 2009; Sen et al. 2012).

We now report novel overlapping de novo noncoding deletion copy-number variants (CNVs) located 96–257 kb upstream of *FOXF1* in seven patients with ACD/MPV, who all died in the first month of life with severe respiratory distress and pulmonary hypertension. Based on extensive experimental characterization of the microdeletion-defined upstream regulatory region, we propose that paternally incompletely imprinted *FOXF1* is regulated in cis by an interplay between chromatin looping, possibly with contribution of lncRNAs, and methylation-controlled *GLI2* binding.

Results

Noncoding deletion CNVs upstream of *FOXF1*

DNA samples from nine patients with ACD/MPV, negative for point mutations within the *FOXF1* coding exons, were analyzed

by array comparative genomic hybridization (aCGH) for the presence of CNVs in 16q24.1. In sample 59.4, aCGH revealed a 15-kb deletion of the entire *FOXF1* and its promoter. Studies of the remaining eight cases identified CNVs that left the *FOXF1* coding region intact. In patient 41.4, an ~11-kb deletion, mapping 2.6 kb upstream of *FOXF1*, removed one copy of the distal portion of the *FOXF1* promoter, corresponding to *Foxf1* promoter region II in mice (Kim et al. 2005) and overlapping with a portion of the lncRNA gene *FOXF1-AS1* (also known as *lncFOXF1* [Khalil et al. 2009] and *TCONS_00024240*) (Ota et al. 2004). We show by RT-PCR and DNA sequencing that *FOXF1-AS1* is expressed in normal human newborn lungs (Supplemental Fig. S1). In the remaining seven patients, overlapping deletions, ranging in size from 140 kb to 2625 kb, mapped 96–257 kb upstream of *FOXF1* (Fig. 1; Supplemental Table S1).

To better estimate the recurrence risk for these deletions, we mapped and sequenced the deletion breakpoints of six of the upstream microdeletions (patients 57.3, 60.4, 64.5, 77.3, 95.3, and 96.3) (Supplemental Fig. S2; Supplemental Table S1) and the microdeletion that included the *FOXF1* gene (patient 59.4) (Supplemental Fig. S2). Microhomology was identified in five of seven breakpoint junctions (patients 57.3, 60.4, 64.5, 77.3, and 95.3), consistent with the deletions arising by a template switching replicative mechanism such as FoSTeS/MMBIR (Lee et al. 2007; Hastings et al. 2009). In three of these five cases, both deletion breakpoints mapped within *Alu* elements (Supplemental Table S1). The probability of finding both breakpoints in *Alu* elements by chance was estimated at less than 0.0066 (Supplemental Fig. S3), thus being much lower than the observed frequency of finding breakpoints of ACD/MPV microdeletions in *Alu* repetitive elements. This finding suggests a mechanistic link between *Alu* sequences and the location of microdeletion breakpoints. Interestingly, in patients 64.5 and 95.3, the distal breakpoints were located within the same copy of an *AluSx* element (~100 bp apart), thus defining




Figure 1. Nine (two published—D9, D10—and seven novel) ACD/MPV-causing microdeletions share a 75-kb putative regulatory region (SDR), mapping 257 kb upstream of *FOXF1* (16q24.1). Array CGH plots of two deletions defining SDR are shown.

a potential breakage-prone hotspot. In patient 59.4, the breakpoints occurred within highly homologous regions of the low-complexity/GC-rich repeats and SINE/MIR repeats. We did not find any evidence for low-level somatic mosaicism in parental blood samples using PCR for patient-specific junction fragments; all microdeletions appear to have occurred de novo (Supplemental Fig. S4).

Regulatory region upstream of *FOXF1*

Sequence alignments of the seven distant microdeletions showed that they share a 75-kb region 257 kb upstream of *FOXF1* (chr16:86,212,040–86,287,054; shared deletion region, SDR) (Fig. 1; Supplemental Table S1). We found that the SDR represents a protein–gene desert (<http://genome.ucsc.edu>). Nevertheless, this genomic region harbors DNA segments that are evolutionarily conserved among land vertebrates and have high 7× regulatory potential (Fig. 2A). Hence, we hypothesized that the SDR may contain regulatory site(s) controlling the *FOXF1* promoter.

Interestingly, we also found that the SDR encompasses one locus (chr16:86,223,827–86,234,547) and part of another locus (chr16:86,254,429–86,338,058), encoding differentially spliced putative lncRNAs exhibiting increased expression in the lungs (<http://genome.ucsc.edu>). The 43.5-kb EST CR737045 (chr16:86,259,186–86,302,689), part of the 79-kb lncRNA *TCONS_00024764*, is specifically expressed in fetal lungs (SOURCE at <http://source.stanford.edu>). We show, by RT-PCR and sequencing, that *TCONS_00024764* lncRNA gene is also expressed in normal newborn lung at a much higher level than in HEK293 kidney cells and lymphoblasts (Supplemental Fig. S1).

We further narrowed SDR to ~10-kb Segment 1 of the highest 7× regulatory potential and sequence conservation (Fig. 2A), containing a cluster of the predicted binding sites for the GLI1, GLI2, and GLI3 transcription factors (GLI-binding sites, consensus sequence: GACCACCCACNNNG [Hallikas et al. 2006]) overlapping with a CpG island (Fragment 1a) (Fig. 2B; Supplemental Fig. S5), and ~8-kb Segment 2 with multiple binding sites for other transcription regulators, and the highest potential for histone methylation and acetylation. Both segments encode lncRNAs expressed in the lungs (Fig. 2A).

GLI2 binds within the upstream regulatory region


Sonic hedgehog (SHH) signaling targets a GLI2 transcription factor and is crucial for early lung development in mice (Rutter et al. 2010) and humans (Zhang et al. 2010). GLI1-3 have been shown to be expressed in human lung mesenchymal tissues, including endothelial cells (Maeda et al. 2007). Moreover, studies in mice have shown that Gli2 regulates *Foxf1* expression in the developing stomach and intestine (Madison et al. 2009), which, together with airway and alveolar tissues, are of endodermal origin. To determine whether in silico-identified GLI-binding sites in the SDR bind GLI2 in vivo, we screened the SDR for the GLI2 binding using a ChIP-chip assay. We detected strong binding of GLI2 to SDR in the cultured human pulmonary microvascular endothelial cells (HPMEC) ($p = 0.007$, $n = 2$) at a region including several in silico-predicted GLI-binding sites (chr16:86,232,498–86,232,882) (Supplemental Figs. S5, S6). Although only one of the GLI-binding sites of SDR perfectly matches the consensus sequence, the clustering of nine of these sites within a 0.2-kb portion of Fragment 1a may have a synergistic effect on GLI2 binding. Given that HPMEC expresses both *FOXF1* and *GLI2* (Supplemental Fig. S7), we hypothesized that GLI2 binding at SDR may regulate *FOXF1* transcription.

GLI2 binding to the distant enhancer regulates *FOXF1* promoter

To this end, we performed a secreted alkaline phosphatase (SEAP) reporter assay in HPMEC (Fig. 3A,B). We prepared plasmid constructs that allow for transient expression of the *SEAP* reporter gene under the control of the *FOXF1* promoter and its putative regulatory sites. The upstream putative regulatory sequences were then tested both in *cis* (inserted into a vector upstream of the *FOXF1* promoter) and in *trans* (placed on another plasmid used in the cotransfection of HPMEC with the *FOXF1* promoter-containing reporter vector). The –5.5-kb *FOXF1* promoter region includes two intervals that remain highly conserved between mice and humans (Kim et al. 2005) and contains, besides the RNA Pol II-binding site (chr16:86,543,198–86,543,374), multiple transcription factor binding sites (<http://genome.ucsc.edu>). When placed upstream of the promoterless *SEAP*, the –5.5-kb promoter region activated *SEAP* transcription 11-fold to 20-fold; this range depended on whether the cells were additionally cotransfected with a pCS2Gli2 vector, constitutively expressing GLI2 ($P < 0.0001$) (Fig. 3A). Madison et al. (2009) demonstrated that the *FOXF1* promoter harbors the evolutionarily conserved (identical among mammalian, bird, fish, and amphibian species) consensus GLI-binding site (chr16:86,539,377–86,539,385) that is deleted in patient 41.4 (Fig. 1). As expected, the truncated version of the *FOXF1* promoter, missing this GLI-binding site, showed weaker *SEAP* expression in comparison with the intact promoter, especially in excess of GLI2 ($P = 0.038$) (Fig. 3A). Of note, several variant GLI-binding sites are still present in the residual truncated promoter region from case 41.4, potentially explaining why it responded, although weakly, to an excess of GLI2 (Fig. 3A). Placement of the 0.6-kb part of Fragment 1a of the SDR, containing GLI-binding sites, upstream of the *FOXF1* promoter increased *SEAP* expression from the *FOXF1* promoter twofold ($P < 0.0016$). Activation of the promoter by the SDR GLI-binding sites in *trans* also increased reporter expression ($P = 0.027$) (Fig. 3B), further suggesting that these GLI-binding sites can regulate *FOXF1* transcription from a distant location, likely through chromatin looping that juxtaposes *FOXF1* promoter and SDR. Moreover, cotransfection of HPMEC with the plasmid pCS2Gli2, constitutively expressing GLI2 protein, increased expression of the *SEAP* reporter from the *FOXF1* promoter in all construct combinations that we tested (Fig. 3A,B), further indicating that *FOXF1* can be regulated in lung endothelial cells by a GLI2 transcription factor. The increase of *FOXF1* transcription from the –5.5-kb *FOXF1* promoter alone, in response to the extra GLI2 synthesis, most likely results from binding of GLI2 to the mentioned consensus GLI-binding site or any of several GLI-binding site variants located within 5.5 kb upstream of *FOXF1*.

Using the *SEAP* reporter assay, we also tested an in silico-identified putative regulatory Segment 2, located ~16 kb distally to the Segment 1 (Fig. 2A). This region was indicated by ChIP-seq assays to bind CTCF and several transcription factors other than GLI2 (<http://genome.ucsc.edu>). In the presence or absence of excess GLI2, a 1.4-kb fragment (chr16:86,256,619–86,258,038) of Segment 2 appeared to have no effect on the *SEAP* expression from the *FOXF1* promoter when subcloned next to the *FOXF1* promoter in the same orientation as the promoter, but increased the promoter activity fivefold when placed in the opposite orientation ($P < 0.0001$) (Fig. 3A). When tested in *trans*, the 1.4-kb fragment of Segment 2 did not significantly affect the *FOXF1* promoter activity (Fig. 3B). Thus, in contrast to the GLI-binding sites of Fragment 1a,

A



B




Figure 2. Characterization of the SDR. (A) Segment 1 (~10 kb; black rectangle) and Segment 2 (~8 kb; red rectangle), harboring, among others, transcription factor binding sites and a part of the fetal lung-expressed lncRNA gene, are shown. The figure is drawn according to the 2009 Human Reference Sequence (GRCh37/hg19). (B) Insight into the ~1.5-kb Fragment 1a showing (from top to bottom) the bisulfite sequenced region, methylation array oligo probes (red arrows) that indicate differential methylation, differentially methylated CpG island, ChIP-chip GLI2-binding region, 7× regulatory potential, mammalian evolutionary conservation, and CG content.




Figure 3. Distant regulatory region, SDR, controls the activity of the *FOXF1* promoter. (A,B) Results of the reporter assay experiments showing regulation of the *FOXF1* promoter in HPMEC by fragments of Segments 1 and 2 of the SDR. (*FOXF1p*) *FOXF1* promoter (0–5.5 kb upstream of ATG codon) cloned in pSEAP2Basic; (41.4delp) truncated *FOXF1* promoter (0 to –3.0 kb, ACD case 41.4) cloned in pSEAP2Basic; (Seg1 *FOXF1p*) distant upstream GLI-binding region (part of Fragment 1a) and *FOXF1* promoter cloned in pSEAP2Basic; (Seg2>*FOXF1p*) Segment 2 putative enhancer and *FOXF1* promoter cloned in pSEAP2Basic in the same orientation; Seg2<*FOXF1p*, the same enhancer in reverse orientation and *FOXF1* promoter cloned in pSEAP2Basic; (vect) pGEM-T Easy vector; (Seg1) GLI-binding region of Fragment 1a cloned in pGEM-T Easy; (Seg2) putative enhancer of Segment 2 cloned in pGEM-T Easy. The presence of additional GLI2, constitutively expressed from the pCS2Gli2 vector, is denoted by +GLI2. The GLI-binding region of Fragment 1a stimulates activity of the *FOXF1* promoter in *cis* (A) and in *trans* (B) settings. (C) Results of the 4C experiment revealing long-range physical interaction between the *FOXF1* promoter and SDR. Coordinates of the SDR region interacting with the *FOXF1* promoter (SDR-promoter interaction peaks) in HPMEC are (from top) 86,246,725–86,246,982 (0.05 < FDR ≤ 0.1) and 86,246,125–86,246,982 (0.1 < FDR ≤ 0.2). The two HPMEC panels represent results of independent experiments. No SDR-*FOXF1* promoter interaction peak was detected in lymphoblasts, which do not express *FOXF1*.

the tested fragment of Segment 2 seems unlikely to contribute to the long-range control of the *FOXF1* expression.

SDR-*FOXF1* promoter chromatin looping

To determine whether there is a physical interaction between the *FOXF1* promoter and the SDR that would juxtapose distant GLI-binding sites and the *FOXF1* promoter, we performed a chromosome conformation capture-on-chip (4C) analysis. We detected interactions between the *FOXF1* promoter region and regions located upstream of it, including the 75-kb SDR (Fig. 3C). Using two independently prepared 4C libraries from HPMEC, we identified overlapping SDR fragments (chr16:86,246,725–86,246,982 and 86,246,125–86,246,982) interacting with the *FOXF1* promoter fragment (chr16:86,542,571–86,543,312) containing part of the Pol II-binding site that were not detected in the 4C library prepared from control lymphoblasts (Fig. 3C). These SDR fragments map 12 kb distal to Segment 1. Chromatin looping between SDR and the *FOXF1* promoter could occur with a contribution of lncRNAs (Mattick 2009, 2010; Ørom et al. 2010; Wang and Chang 2011), including any of those encoded within SDR. Moreover, CTCF binding within the SDR (Supplemental Fig. S8) also might contribute to the formation of looping architecture (Phillips and Corces 2009). Since we did not detect interactions between SDR and the *FOXF1* promoter in lymphoblasts, we propose that chromatin looping between SDR and the *FOXF1* promoter (Supplemental Fig. S9) allows GLI2 to increase *FOXF1* activity specifically in lung endothelium and other tissues of similar origin.

Maternal origin of ACD/MPV microdeletions

We have determined parental origin for seven out of eight upstream microdeletions (patients 57.3, 60.4, 64.5, 77.3, 81.3, 95.3, and 96.3) and for one microdeletion (59.4) that included the entire *FOXF1*. Interestingly, all these microdeletions arose de novo on the maternal chromosome (Supplemental Tables S1, S2). Six published de novo microdeletions that included *FOXF1* (D1, D3, D4, and D8) or mapped upstream of *FOXF1* (D9 and D10) also arose de novo on the maternal chromosome (Stankiewicz et al. 2009). Moreover, in a recently published unique familial case of ACD/MPV, with missense mutations in *FOXF1* affecting five subjects, the mutation was inherited from a heterozygous healthy mother, in whom the mutation arose de novo on her paternal chromosome (Sen et al. 2012). In aggregate, these findings strongly suggest a parental-origin bias of *FOXF1*-associated CNVs ($P < 0.001$, $n = 14$).

Differential expression of *FOXF1* parental alleles

To further test whether *FOXF1* is imprinted, we compared *FOXF1* expression

levels from both parental chromosomes using two sets of semi-quantitative RT-PCRs with primers designed to differentiate between the two parental chromosomes. We found that whereas both primer sets amplified equal amounts of *FOXF1* from genomic DNA, their amplification from cDNA differed by 27% ($P = 0.011$, $n = 3$) (Supplemental Fig. S10). Thus, our data indicate that *FOXF1* expression from the maternal chromosome is not equal to its expression from the paternal chromosome, further indicating that *FOXF1* is imprinted in humans albeit incompletely.

Differentially methylated CpG site within SDR

Genomic imprinting can be caused by differential methylation of CpG islands, histone modification, or interactions with lncRNAs (Bartolomei 2009). Here, we have investigated in detail CpG methylation as one of the potential mechanisms of *FOXF1* imprinting. The *FOXF1* promoter resides within a large CpG island (Lo et al. 2010). We have bisulfite-sequenced this region of DNA from normal lung and have found that the *FOXF1* promoter is not methylated (Fig. 4A). Previous studies using immortalized normal mammary cells and organoids have also shown that the *FOXF1* promoter is not methylated (Lo et al. 2010). Interestingly, the part of the *FOXF1* CpG island that is included in the *FOXF1* first exon is extensively methylated (Fig. 4A); however, the functional significance of this methylation remains unknown. We also analyzed the results of the methylation studies using Infinium 450K methylation arrays on 39 brain DNA samples from normal individuals (courtesy of Dr. A.L. Beaudet). One of the 13 potentially differentially methylated regions upstream of *FOXF1* encompassed three probes




Figure 4. Methylation of the SDR CpG island decreases SDR potential to activate the *FOXF1* promoter. (A) Methylation status of the *FOXF1* promoter and SDR CpG island in normal fetal lung (a similar CpG methylation pattern was observed in DNA isolated from blood). Each lane represents a separate clone. (●) Methylated CpGs, (○) unmethylated CpGs. (Pink) Location of a cluster of GLI-binding site variants. (Red) Position of the consensus “core” GLI-binding site. Genomic coordinates of the bisulfite sequenced regions are: chr16:86,232,367–86,232,979 (SDR CpG island); chr16:86,542,223–86,542,807 (*FOXF1* promoter 2); chr16:86,543,777–86,543,907 (*FOXF1* promoter 1); chr16:6,544,458–86,545,037 (*FOXF1* exon 1). (B) Dependence of the *FOXF1* promoter activity on the methylation status of the SDR CpG island. The presence of additional GLI2 constitutively expressed from the pCS2Gli2 vector is denoted by +GLI2. (*FOXF1*p) *FOXF1* promoter cloned in pSEAP2Basic; (vect) pGEM-T Easy; (Seg1) GLI-binding region (Fragment 1a) cloned in pGEM-T Easy; (mSeg1) GLI-binding region of Fragment 1a with in vitro-methylated CpG island cloned in pGEM-T Easy; (Seg1*) mock control for mSeg1.

located within the SDR Fragment 1a in the vicinity of a cluster of GLI2-binding sites (Fig. 2B; Supplemental Fig. S5; Supplemental Table S3) identified in the ChIP-chip experiment and functionally verified in the reporter assay. Bisulfite sequencing of the SDR 0.2-kb CpG island closest to the consensus GLI2-binding site and overlapping with several GLI-binding site variants confirmed that it is differentially methylated in the DNA from normal fetal lung (Fig. 4A).

Methylation of CpG island regulates GLI-binding sites

We were interested to know whether methylation of the CpG island, including and neighboring the GLI-binding sites, interferes with the ability of these sites to regulate *FOXF1* expression. To this end, we have methylated (in vitro) half of the C residues of this CpG island in a 0.6-kb portion (chr16:86,232,261–86,232,908) of Fragment 1a. We then cotransfected the methylated construct with a *FOXF1* promoter-harboring reporter plasmid. We observed a reduction in the ability of the Fragment 1a GLI-binding sites to activate the *FOXF1* promoter, following partial methylation of the CpG island ($P = 0.015$) (Fig. 4B). The function of the methylated GLI-binding region did not significantly increase in the presence of excess GLI2 following the cotransfection of HPMEC with pCS2Gli2 (Fig. 4B).

Discussion

We identified overlapping deletions located upstream of *FOXF1* in seven unrelated patients with ACD/MPV, defining a putative distant regulatory region (SDR) for *FOXF1*. This region, located 257 kb 5' to *FOXF1*, is 75 kb in size and contains two smaller segments that are distinguished by high evolutionary conservation among land vertebrates and high $7\times$ regulatory potential (Fig. 2). The ~ 1.5 -kb part of Segment 1 (Fragment 1a) encompasses several GLI-binding sites (Supplemental Fig. S5). GLI2 is essential for lung development in humans and mice (Maeda et al. 2007; Madison et al. 2009; Rutter et al. 2010; Zhang et al. 2010). Using a ChIP-chip assay, we have confirmed binding of GLI2 to Fragment 1a in HPMEC (Supplemental Fig. S6). The 0.6-kb GLI2-binding portion of Fragment 1a significantly increased transcription from the *FOXF1* promoter in our reporter assay, further indicating that it may regulate *FOXF1* in vivo (Fig. 3A,B). The increase of *FOXF1* transcription occurred not only in *cis* but also in *trans*, suggesting that this activation could occur in vivo through chromatin looping that juxtaposes the *FOXF1* promoter and SDR. The CTCF binding within the SDR (Supplemental Fig. S8) may contribute to the formation of this looping architecture (Phillips and Corces 2009). Both *cis* and *trans* activations of the *FOXF1* promoter seem to be specific, since (1) substitution of the 0.6-kb sequence from the 1.5-kb Fragment 1a with a 1.4-kb fragment of Segment 2, harboring sites for transcription factors other than GLI2, in *trans* or in *cis* in its original genomic orientation had no effect on the promoter activity; and (2) the 3-kb empty vector pGEM-T Easy did not activate the *FOXF1* promoter.

We supported the chromatin looping hypothesis via 4C studies, in which we identified physical interaction of the SDR with the *FOXF1* promoter close to the Pol II-binding site (Fig. 3C). This interaction brings the distant GLI2-binding sites to the proximity of the *FOXF1* promoter. Although only one of the distant GLI-binding sites of SDR perfectly matches the consensus "core" sequence, the clustering of nine of these sites within this segment may have synergistic effects on GLI2 binding. Moreover,

the variant GLI-binding sites with relatively low affinity have been recently shown to strongly induce transcription when present in native promoters (Winklmayr et al. 2010). Since we did not detect interactions between SDR and the *FOXF1* promoter in lymphoblasts, where *FOXF1* is not expressed, we propose that chromatin looping between SDR and *FOXF1* allows GLI2 to increase *FOXF1* activity specifically in lung endothelium.

Importantly, we have also identified putative lncRNA genes within the SDR region (Fig. 2A). LncRNAs play a crucial role in embryonic development (Ulitsky et al. 2011). Moreover, lncRNAs have been proposed to play a role in imprinting and both in *cis* and in *trans* regulation of gene expression by acting as scaffolds for chromatin-modifying complexes and nuclear bodies, as enhancers as well as mediators of long-range chromatin interactions (Guttman et al. 2009; Mattick 2009, 2010; Nagano and Fraser 2011; Wang and Chang 2011). Thus, it seems tempting to speculate that some of the lung-expressed lncRNAs may be needed for tissue-specific interaction of the *FOXF1* promoter with the distant regulatory regions. LncRNAs can also guide chromatin-modifying complexes to specific genomic loci to regulate gene expression (Mattick 2010). For instance, Khalil et al. (2009) showed that a 34-kb lncRNA *FOXF1-AS1*, mapping 1.7 kb upstream of *FOXF1*, binds the Polycomb repressive complex PRC2. Of note, this lncRNA has the highest expression in human lungs (<http://genome.ucsc.edu>) (see also Supplemental Fig. S1) and partially overlaps with the *FOXF1* promoter, and its locus is largely deleted in the ACD/MPV case 41.4. Our preliminary experiments on *FOXF1-AS1* knock-down using siRNAs showed that $\sim 50\%$ decrease of *FOXF1-AS1* expression in HPMEC resulted in a weak increase of *FOXF1* transcription (Supplemental Fig. S1), supporting its suggested function as a transcriptional repressor (Khalil et al. 2009). However, in case 41.4, in addition to the *FOXF1-AS1* gene, a GLI-binding consensus sequence is also deleted, likely leading to a net decrease of *FOXF1* expression.

Intriguingly, all of the deletions for which we were able to determine the parental chromosome origin arose on maternal chromosome 16, strongly suggesting that *FOXF1* could be paternally imprinted ($P < 0.001$, $n = 14$). The paternal imprinting of *FOXF1* has been also predicted bioinformatically (Luedi et al. 2007). Even so, any paternal imprinting is probably incomplete, because paternal uniparental disomy of chromosome 16 (UPD16pat) has been reported in a child with only prenatal and postnatal growth retardation (Kohlhase et al. 2000). Our data showing differential expression of *FOXF1* in the lungs support a partial imprinting hypothesis (Supplemental Fig. S10). We also reported a paternally inherited no-stop mutation (last codon) in *FOXF1* in a patient with ACD/MPV (Stankiewicz et al. 2009). We hypothesize that the extended *FOXF1* RNA transcript might have escaped nonsense-mediated decay and negatively interacted with the wild-type copy, resulting in ACD/MPV.

We have investigated in detail CpG methylation as a potential mechanism of *FOXF1* imprinting. The *FOXF1* promoter resides within a large CpG island (Lo et al. 2010), which is not methylated in normal lung tissue (Fig. 4A). Using genome-wide differential methylation array hybridization and bisulfate sequencing, we found that a small CpG island, located within Fragment 1a of SDR and overlapping with GLI-binding sites, is differentially methylated. Using in vitro methylation and reporter assays, we showed that the methylation of this distant CpG island compromises the ability of its GLI-binding region to activate the *FOXF1* promoter in vitro (Fig. 4B). Although only two of the GLI-binding site variants include CpGs within their sequence and thus can be directly affected

by CpG methylation, it is likely that methylation of the CpG island changes the local DNA environment, resulting in the decrease of affinity of its GLI-binding sites for GLI2. Interestingly, methylation of CpGs has been also shown to inhibit interaction with DNA of the GLI-type zinc-finger factor YY1 (Kim et al. 2003).

Position effect or *cis*-ruption disorders are defined as conditions arising due to disruption of the *cis* regulatory genomic architecture of a disease gene locus (Kleinjan and van Heyningen 2005; Kleinjan and Coutinho 2009). To date, this phenomenon has been reported for more than 40 genetic loci in the human genome; however, the underlying mechanism remains unknown. Of interest, a 7.4-kb *cis*-regulatory deletion disrupting conserved noncoding sequences and their interaction with the promoter of another FOX gene, *FOXL2*, mapping more than 280 kb apart, has been described as pathogenic for blepharophimosis, ptosis, and epicanthus inversus (BPES, OMIM 110100) (D'haene et al. 2009). In addition, genomic deletions and an apparently balanced translocation breakpoint mapping over 250-kb downstream from *FOXG1* have been reported in patients with a congenital variant Rett syndrome (OMIM 613454) (Kortüm et al. 2011; Ellaway et al. 2012), suggesting that also other FOX genes may be regulated by long-range chromatin *cis*-interactions. Recently, Guttman et al. (2011) successfully knocked down genome-wide 147 (out of 226) lncRNAs using shRNAs and observed gene dysregulation both in *trans* and *cis*, with *cis* effects ranging up to 300 kb. Our findings further suggest that lncRNA-controlled gene regulation could be responsible for the position effect phenomenon in humans and potentially cause many other disorders of development.

In summary, we propose a model of long-range regulation of *FOXF1* expression in the lungs that includes CpG methylation-controlled GLI2 binding at a distant tissue-specific enhancer, whereby chromosomal looping, likely mediated by lncRNAs and/or CTCF, juxtaposes this enhancer and the *FOXF1* promoter.

Methods

Subject recruitment

DNA samples were collected from nine unrelated probands clinically and histopathologically diagnosed with ACD/MPV. All patients died from severe pulmonary insufficiency and hypertension in the first month of life.

DNA and RNA isolation, and DNA sequencing

Peripheral blood DNA was extracted using the Genra Puregene Blood Kit (QIAGEN). DNA from frozen lung tissues was extracted using the DNeasy Blood & Tissue Kit (QIAGEN). DNA from FFPE lung tissues was isolated following the manufacturer's protocol (Agilent Technologies). RNA from cultured HPMEC was extracted using the RNeasy Protect Mini Kit (Invitrogen). Lung RNA was isolated from frozen tissues using the Illustra TriplePrep Kit (GE Healthcare).

PCR products and plasmid DNA were sequenced by the Sanger method (Lone Star Labs). Before cycle sequencing, PCR products were treated with ExoSAP-IT (USB) to remove unincorporated nucleotides and primers.

DNA sequence analysis

Reference sequences were downloaded from the UCSC Genome Browser (NCBI build 37/hg19; <http://genome.ucsc.edu>). DNA sequence similarities were analyzed using BLAT ([\[ucsc.edu\]\(http://genome.ucsc.edu\)\). Evolutionary conservation and regulatory potential of the analyzed sequences were assessed using the UCSC "Conservation" and "7× Reg potential" tracks, respectively. The 7× regulatory potential scores are computed from alignments of human, chimpanzee, macaque, mouse, rat, dog, and cow genomes using log-ratios of transition probabilities from two variable order Markov models \(Kolbe et al. 2004; King et al. 2005\). Sequences were assembled using Sequencher v4.8 \(GeneCodes\). Repetitive sequences were identified using RepeatMasker \(<http://repeatmasker.org>\). GC content was determined using CpGPlot \(<http://ebi.ac.uk/Tools/emboss/cpgplot>\). CTCF-binding hotspots were identified using the University of Washington CTCF binding site track from the UCSC Genome Browser \(ChIP-Seq determined\) using a threshold value of 500. *P*-values of finding microdeletion with both breakpoints in *Alu* family repetitive elements by chance were calculated using an approach similar to the one presented by de Smith et al. \(2008\) \(see also Supplemental Methods\).](http://genome.</p>
</div>
<div data-bbox=)

Screening *FOXF1* for mutations

The entire coding region of *FOXF1* (two exons) and its splicing sites were amplified for each patient in partially overlapping fragments using GoTaq Flexi DNA Polymerase (Promega) in the presence of 8% DMSO. The PCR conditions were 25 cycles of incubation for 30 sec at 94°C, 30 sec at 56°C, and 30 sec at 72°C. Following purification, PCR products were directly sequenced. DNA sequences were then compared with the *FOXF1* reference sequence (NM_001451.2).

Genomic copy-number analysis

CNVs were identified by aCGH with either custom-designed 16q24.1 region-specific (1 Mb flanking *FOXF1*) 180K oligonucleotide microarrays (Agilent Technologies) or 4.2M genome-wide oligonucleotide microarrays (Roche-NimbleGen). 4×180 microarrays were scanned using an Agilent DNA Microarray Scanner, and the data were analyzed using Agilent Genomic Workbench software. 4.2M microarrays were scanned on a Roche-NimbleGen MS 200 Microarray Scanner. Scanned images of the arrays were processed using NimbleScan v2.5 (Roche NimbleGen) and analyzed using SignalMap v1.9 (Roche NimbleGen).

Amplification and sequencing of microdeletion breakpoints

PCR primers flanking each microdeletion (Supplemental Table S4) were designed using Primer3 v0.4.0 software (<http://frodo.wi.mit.edu/primer3/>). Amplification of 5- to 12-kb junction fragments for sequencing was performed using LA Taq polymerase (TaKaRa Bio USA).

Parental origin of microdeletions

Parental origin of microdeletions was determined following identification of informative SNPs in parental and patients' chromosomes. Regions containing the potentially informative SNPs were amplified by PCR and directly sequenced. The primers used in this analysis were designed based on the location of known SNPs.

ChIP-chip analysis

Chromatin immunoprecipitation with anti-GLI2 antibody was conducted in HPMEC (ScienCell Research Laboratories). Expression of *FOXF1* and *GLI2* in these cells was confirmed by RT-PCR using the SuperScript One-Step RT-PCR Kit (Invitrogen) (Supple-

mental Fig. S7; Supplemental Table S5). The reference DNA was extracted from skin fibroblasts that do not express *FOXF1*. HPMEC were cultured to confluence in EMS medium supplemented with 10% FBS, ECGS, and 1% penicillin-streptomycin (ScienCell Research Laboratories) at 37°C with 5% CO₂. Fibroblasts were cultured in DMEM medium (Invitrogen), supplemented with 10% FBS and 1% penicillin-streptomycin, at 37°C with 10% CO₂. Because of low levels of endogenous *GLI2* expression, cells were transfected, 24 h before the assay, with *GLI2*-expressing plasmid pCS2*GLI2* (Roessler et al. 2005) (Addgene) (1 µg of DNA/60-mm plate) using Lipofectamine LTX and Plus Reagent (Invitrogen). Protein-chromatin interactions were captured by incubating cells with 1% formaldehyde for 10 min at room temperature. Cells were then lysed in SDS lysis buffer and sonicated. Fragmentation of the DNA to ~1-kb fragments was verified by agarose gel electrophoresis. Immunoprecipitation was performed using an EZ ChIP kit (Millipore) and anti-*GLI2* antibody (R&D Systems). Five microliters of the anti-*GLI2* antibody was added to 1 mL of the sample, and the *GLI2*-DNA complex was immunoprecipitated overnight at 4°C. Twenty microliters of Normal Sheep IgG (R&D Systems) was used as a negative control. Anti-mono/di/tri methyl-histone H3 (lys4) clone AW304 rabbit monoclonal IgG (Upstate) was used as a positive control. The MinElute PCR Purification Kit (QIAGEN) was used to purify and concentrate DNA to a final volume of 10 µL. Immunoprecipitated DNA was then amplified using the GenomePlex Complete Whole Genome Amplification Kit (Sigma-Aldrich). After amplification, samples were labeled with Cyanine dUTP (Agilent Technologies) using the Agilent Genomic DNA Enzymatic Labeling Kit and used for array hybridization for 24 h at 65°C on a custom-designed 16q24.1-region-specific 4x180K oligonucleotide microarray (Agilent Technologies).

Reporter assay constructs

The -5.5-kb *FOXF1* promoter region (chr16: 86,538,679–86,544,175), directly upstream of the *FOXF1*'s AUG initiation codon, was amplified by PCR from genomic DNA isolated from the blood sample of a normal control individual. This region contained the entire 43-bp-long 5'-untranslated part of the *FOXF1* first exon. The primers used for the amplification were Foxp2F2: 5'-CTAGCTAGCACATTTCCTCATATCTGTGTAGAGAGCACCT-3' and FoxAUG2R: 5'-TTGCGCCGATTCGAACGGGTGGCTGCTG-3', and included restriction sites for *NheI* and *BstBI*, respectively. PCR was done using LA Taq DNA polymerase (TaKaRa Bio) in the presence of 6% DMSO, applying 25 cycles of 30 sec at 94°C and 5 min at 68°C. Following digestion with *NheI* and *BstBI* (NEB), the PCR product was cloned between *NheI* and *BstBI* sites of the multiple cloning site of the promoterless SEAP reporter vector, pSEAP-Basic (Clontech), generating a plasmid, p5.5FoxSEAP. The pSEAP2-Control vector, containing the constitutive SV40 early promoter with its enhancer, was used as a positive control in the assay. The plasmid p41.4Δ4, containing the truncated version of the 5.5-kb *FOXF1* promoter region (devoid of its 5' portion deleted in an ACD/MPV case 41.4) was constructed by digesting the p5.5FoxSEAP with *KpnI* and relegating the remaining portion of the vector. A 0.6-kb portion of Fragment 1a (chr16:86,232,261–86,232,908), bearing CpG island and *GLI2*-binding sites, was amplified from genomic DNA of a normal control individual using Taq DNA polymerase (Invitrogen) and the following primers: upsdelCGliF: 5'-GTGCTAGCATGGTGTAAATCACCTGACAGTAAACACT-3' and upsdelCGliR1: 5'-GTGCTAGCGATCTATTCTGCTACTACCTCTGCTTTCC-3', both encompassing the *NheI* site. PCR conditions were 25 cycles of 30 sec at 94°C, 30 sec at 58°C, and 1 min at 72°C. This 0.6-kb fragment was then cloned both into pGEM-T

Easy (Promega) by T-vector cloning to create pGliTEasy, and, following digestion with *NheI*, into the *NheI* site of p5.5FoxSEAP, upstream of the 5.5-kb *FOXF1* promoter region, generating pGli5.5FoxSEAP. The 1.4-kb putative enhancer region of Segment 2 (chr16:86,256,619–86,258,038) was amplified by PCR using *Pfu* Ultra DNA polymerase (Stratagene) with the primers upsdelEnhF: 5'-AAACTTCATCTCTCCCTGCAGCTTCTCTGT-3' and upsdelEnhR: 5'-GTTGGACTCTGAAATCAGTGCCTTCAACAT-3'. The blunt-ended PCR product was A-tailed using GoTaq Flexi DNA polymerase and cloned in the pGEM-T Easy vector to generate plasmid pEnhTEasy. This new vector was then cut with *NheI*, and the putative enhancer-containing fragment was subcloned in the *NheI* site of p5.5FoxSEAP, generating the plasmid pEnh5.5FoxSEAP.

Cell transfection and reporter assay

The HPMEC were cultured as described above. Transient transfection of HPMEC with reporter gene constructs was done by electroporation using the NEON transfection system (Invitrogen). The electroporation parameters were as follows: pulse voltage, 1350 V; pulse width, 30 msec; pulse number, 1; cell density, 1.0×10^7 cells/mL. The transfection efficiency was between 20% and 30%. One-half microgram of pSEAP2Basic (no promoter), pSEAP2Control (Clontech), pEnhTEasy, pUpstdeGLiTEasy, or 1 µg of p5.5FoxSEAP, pGli5.5FoxSEAP, or pEnh5.5FoxSEAP was cotransfected with 0.1 µg of pMetLuc-Control (Clontech) (internal control for transfection efficiency) and with or without 0.4 µg of pCS2*GLI2* in 24-well plate setting.

In an *in vitro* methylation experiment, 3 µg of linearized, methylated, or nonmethylated pUpstdeGLiTEasy vector was cotransfected with p5.5FoxSEAP and pMetLucControl. One set of transfections included also pCS2*GLI2*. Each well of 24-well plates was seeded with 1.5×10^5 cells. Activities of SEAP and *Metridia* luciferase (MetLuc) were measured 55 h later by a luminescence assay using the Ready-to-Glow Dual Secreted Reporter System (Clontech) according to the manufacturer's protocol. Luminescence was recorded using microplate LUMIstar Omega luminometer (BMG Labtech). SEAP activities of individual transfections were normalized for *Metridia* luciferase activities. Results are shown as the mean of three independent experiments. Statistical significance of the observed differences was estimated applying an unpaired *t*-test.

4C analysis

3C libraries were generated according to the protocol described by Dostie and Dekker (2007) using 1×10^7 HPMEC or lymphoblasts. Cross-linked DNA was digested with *EcoRI* overnight, and religated with T4 ligase for 4 h at 16°C at low DNA concentration. The 3C library was then processed according to the procedure described by Simonis et al. (2007). The ligation junctions were trimmed by digestion of 3C library with *TaqI* overnight, followed by phenol:chloroform extraction, religation at low DNA concentration for 4 h at 16°C, and DNA linearization with *HindIII* overnight at 37°C. The 4C template was created by linear amplification of DNA using the Expand Long Template PCR System (Roche Applied Science). Two hundred nanograms of 4C template was amplified per reaction. The primers used for amplification were 5'-GGCAGGAAGTTTACAGGGTTTAACG-3' and 5'-TGTGTGTGCTAATGTGTGGACAAGA-3'. The primers were designed within the *EcoRI*-*TaqI* fragment (chr16:86,542,571–86,543,312), containing part of the Pol II binding site. The PCR cycling conditions were 30 sec at 94°C, 1 min at 55°C, and 3 min at 68°C. Sixteen reactions were conducted for each template. Pooled PCR products were purified using the MinElute PCR Purification Kit (QIAGEN).

As a reference DNA for hybridization, we used uncross-linked DNA isolated from HPMEC or lymphoblasts with Puregene Blood Core Kit A, and digested overnight with EcoRI and Taq^I.

Custom-designed 720K microarrays covering 2-Mb regions flanking *FOXF1* were designed and produced by Roche-NimbleGen. Labeling and hybridization of 4C DNA libraries were done according to the manufacturer's instructions (Roche-NimbleGen). The arrays were scanned on a NimbleGen 200 Microarray Scanner, and the data were analyzed using NimbleScan v2.5 and SignalMap v1.9. The 4C peak data were generated from the scaled log₂ ratio data. Peaks were detected by searching four or more probes whose signals are above the specified cutoff values, using a 500-bp sliding window. Each peak was assigned a false discovery rate (FDR) score. Scores ≤0.2 are indicative of an interaction site.

Bisulfite sequencing

Bisulfite modification of lung and blood DNA for sequencing was performed using the EpiTect Bisulfite Kit (QIAGEN). Primers for methylation PCR were designed using MethPrimer software (<http://urowgene.org/methprimer/index1.html>) (Supplemental Table S6; Li and Dahiya 2002). PCR was performed in a 25-μL reaction mixture containing 200 ng of bisulfite-treated DNA, 0.5 nmol of each primer, and 1.25 units of HotStarTaq polymerase (QIAGEN). The cycling conditions were 1 min at 95°C, 30 sec at 50°C–62°C, and 1 min at 72°C. PCR products ranging from 0.2 to 0.6 kb were purified from unincorporated primers and nucleotides using the QIAquick PCR Purification Kit (QIAGEN), and T-vector cloned in DH5α cells using the pGEM-T Easy Vector System. Plasmid minipreps were prepared from 25 randomly selected transformant colonies using the Perfectprep Plasmid Mini Kit (Eppendorf) and sequenced using T7 and SP6 promoter universal primers.

In vitro methylation of CpG island

For the in vitro methylation assay, the pUpstdeGliTEasy vector was first linearized using the SphI restriction nuclease (NEB) and then treated with HpaII methyltransferase (NEB), which methylates the internal C residue of the sequence CCGG. The 25-μL reaction mixture contained 1 μg of the DNA, 1 unit of HpaII methylase, 50 mM Tris-HCl (pH 7.5), 10 mM EDTA, 5 mM 2-mercaptoethanol, and 80 μM S-adenosylmethionine. Methylation was performed for 1 h at 37°C. In the mock-methylation reaction, S-adenosylmethionine was omitted. Plasmid DNA was subsequently extracted with phenol:chloroform, precipitated with isopropanol, and analyzed for the degree of methylation by digestion with HpaII restriction nuclease (NEB). Completely methylated plasmid DNA was then used for transfections; unmethylated DNA was used as a control. The stability of methylation following transfection of the methylated construct was demonstrated recently in the similar experiments reported by Ilan and Katzav (2012) and Matousková et al. (2006).

Analysis of *FOXF1* expression from individual parental chromosomes

To determine whether there is a difference in *FOXF1* expression from maternal versus paternal chromosomes, we first looked for heterozygous SNPs in *FOXF1* exons in genomic DNA extracted from normal newborn lung tissue, from which we also extracted RNA. We identified heterologous SNP G>G/A (chr16:86,547,496) within *FOXF1* exon 2. We then performed two sets of RT-PCR, using RNA with reverse primer in one setting ending in a G nucleotide (FoxE2RnaRG: 5'-CAGAAAGTTTACAGTAGAGGTTGGG-3')

and, in the other setting, in an A nucleotide (FoxE2RnaRA: 5'-CAGA AAGTTTACAGTAGAGGTTGGA-3'). The forward primer was the same in both settings (FoxE2RnaF1: 5'-GTCTCCCTTTAGAGCCG TCTTTTG-3'). Both pairs of primers were checked for their equal efficiency in priming PCR using genomic DNA. Semiquantitative RT-PCR was done using the SuperScript One-Step RT-PCR Kit. cDNA was synthesized for 30 min at 50°C. The temperature profile of PCR was 19 cycles of 30 sec at 94°C, 45 sec at 56°C, and 45 sec at 72°C, and a final extension for 5 min at 72°C.

Data access

The aCGH, ChIP-chip, and 4C data sets can be accessed through the NCBI Gene Expression Omnibus (GEO) (<http://www.ncbi.nlm.nih.gov/geo/>) under accession number GSE39258.

Acknowledgments

We thank C. Brown for the access to the electroporation system; M. Withers for technical assistance; C. Dugauquier for histopathological analysis; and J. Bondaruk, A. Gambin, T. Gambin, V.V. Kalinichenko, J.R. Lupski, A. Rodriguez, and C. Shaw-Smith for helpful discussion. Part of this work was supported by NIH grant 1R01HL101975-01 to P. Stankiewicz, a NORF grant and Pilot Project Award from the Texas Children's Hospital to P. Sen, and the Polish National Science Center grant 2011/01/B/NZ2/00864 and the European Social Fund (UDA-POKL.04.01.01-00-072/09-00) to P.D.

References

- Bartolomei MS. 2009. Genomic imprinting: Employing and avoiding epigenetic processes. *Genes Dev* **23**: 2124–2133.
- Birney E, Stamatoyannopoulos JA, Dutta A, Guigó R, Gingeras TR, Margulies EH, Weng Z, Snyder M, Dermitzakis ET, Thurman RE, et al. 2007. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. *Nature* **447**: 799–816.
- Bishop NB, Stankiewicz P, Steinhorn RH. 2011. Alveolar capillary dysplasia. *Am J Respir Crit Care Med* **184**: 172–179.
- Bozyk PD, Popova AP, Bentley JK, Goldsmith AM, Linn MJ, Weiss DJ, Hershenson MB. 2011. Mesenchymal stromal cells from neonatal tracheal aspirates demonstrate a pattern of lung-specific gene expression. *Stem Cells Dev* **20**: 1995–2007.
- Chang VW, Ho Y. 2001. Structural characterization of the mouse *Foxf1a* gene. *Gene* **267**: 201–211.
- de Smith AJ, Walters RG, Coin LJ, Steinfeld I, Yakhini Z, Sladek R, Froguel P, Blakemore AI. 2008. Small deletion variants have stable breakpoints commonly associated with *Alu* elements. *PLoS ONE* **3**: e3104. doi: 10.1371/journal.pone.0003104.
- D'haene B, Attanasio C, Beysen D, Dostie J, Lemire E, Bouchard P, Field M, Jones K, Lorenz B, Menten B. 2009. Disease-causing 7.4 kb *cis*-regulatory deletion disrupting conserved noncoding sequences and their interaction with the *FOXL2* promoter: Implications for mutation screening. *PLoS Genet* **5**: e1000522. doi: 10.1371/journal.pgen.1000522.
- Dostie J, Dekker J. 2007. Mapping networks of physical interactions between genomic elements using 5C technology. *Nat Protoc* **2**: 988–1002.
- Ellaway CJ, Ho G, Bettella E, Knapman A, Collins F, Hackett A, McKenzie F, Darmanian A, Peters GB, Fagan K, et al. 2012. 14q12 microdeletions excluding *FOXP1* give rise to a congenital variant Rett syndrome-like phenotype. *Eur J Hum Genet*. doi: 10.1038/ejhg.2012.208.
- Eulmesekian P, Cutz E, Parvez B, Bohn D, Adatia I. 2005. Alveolar capillary dysplasia: A six-year single center experience. *J Perinat Med* **33**: 347–352.
- Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, Huarte M, Zuk O, Carey BW, Cassady JP, et al. 2009. Chromatin signature reveals over a thousand highly conserved large noncoding RNAs in mammals. *Nature* **458**: 223–227.
- Guttman M, Donaghey J, Carey BW, Garber M, Grenier JK, Munson G, Young G, Lucas AB, Ach R, Bruhn L, et al. 2011. lincRNAs act in the circuitry controlling pluripotency and differentiation. *Nature* **477**: 295–300.
- Hallikas O, Palin K, Sinjushina N, Rautiainen R, Partanen J, Ukkonen E, Taipale J. 2006. Genome-wide prediction of mammalian enhancers based on analysis of transcription-factor binding affinity. *Cell* **124**: 47–59.

- Hastings PJ, Lupski JR, Rosenberg SM, Ira G. 2009. Mechanisms of change in gene copy number. *Nat Rev Genet* **10**: 551–564.
- Ilan L, Katzav S. 2012. Human Vav1 expression in hematopoietic and cancer cell lines is regulated by c-Myb and by CpG methylation. *PLoS ONE* **7**: e29939. doi: 10.1371/journal.pone.0029939.
- Kaestner KH, Knochel W, Martinez DE. 2000. Unified nomenclature for the Winged helix/Forkhead transcription factors. *Genes Dev* **14**: 142–146.
- Kalinichenko VV, Lim L, Stolz DB, Shin B, Rausa FM, Clark J, Whitsett JA, Watkins SC, Costa RH. 2001. Defects in pulmonary vasculature and perinatal lung hemorrhage in mice heterozygous null for the *Forkhead Box f1* transcription factor. *Dev Biol* **235**: 489–506.
- Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D, Thomas K, Presser A, Bernstein BE, van Oudenaarden A, et al. 2009. Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. *Proc Natl Acad Sci* **106**: 11667–11672.
- Kim J, Kollhoff A, Bergmann A, Stubbs L. 2003. Methylation-sensitive binding of transcription factor YY1 to an insulator sequence within the paternally expressed imprinted gene, *Peg3*. *Hum Mol Genet* **12**: 233–245.
- Kim IM, Zhou Y, Ramakrishna S, Hughes DE, Solway J, Costa RH, Kalinichenko VV. 2005. Functional characterization of evolutionarily conserved DNA regions in *Forkhead box f1* gene locus. *J Biol Chem* **280**: 37908–37916.
- King DC, Taylor J, Elnitski L, Chiaromonte F, Miller W, Hardison RC. 2005. Evaluation of regulatory potential and conservation scores for detecting cis-regulatory modules in aligned mammalian genome sequences. *Genome Res* **15**: 1051–1060.
- Kleinjan DJ, Coutinho P. 2009. Cis-rupture mechanisms: Disruption of cis-regulatory control as a cause of human genetic disease. *Brief Funct Genomics Proteomics* **8**: 317–332.
- Kleinjan DA, van Heyningen V. 2005. Long-range control of gene expression: Emerging mechanisms and disruption in disease. *Am J Hum Genet* **76**: 8–32.
- Kohlhase J, Janssen B, Weidenauer K, Harms K, Bartels I. 2000. First confirmed case with paternal uniparental disomy of chromosome 16. *Am J Med Genet* **91**: 190–191.
- Kolbe D, Taylor J, Elnitski L, Eswara P, Li J, Miller W, Hardison RC, Chiaromonte F. 2004. Regulatory potential scores from genome-wide three-way alignments of human, mouse, and rat. *Genome Res* **14**: 700–707.
- Kortüm F, Das S, Flindt M, Morris-Rosendahl DJ, Stefanova I, Goldstein A, Horn D, Klopocki E, Kluger G, Martin P, et al. 2011. The core *FOXF1* syndrome phenotype consists of postnatal microcephaly, severe mental retardation, absent language, dyskinesia, and corpus callosum hypogenesis. *J Med Genet* **48**: 396–406.
- Lai E, Clark KL, Burley SK, Darnell JE Jr. 1993. Hepatocyte nuclear factor 3/Fork head or “winged helix” proteins: A family of transcription factors of diverse biologic function. *Proc Natl Acad Sci* **90**: 10421–10423.
- Langston C. 1991. Misalignment of pulmonary veins and alveolar capillary dysplasia. *Pediatr Pathol* **11**: 163–170.
- Lee JA, Carvalho CM, Lupski JR. 2007. A DNA replication mechanism for generating nonrecurrent rearrangements associated with genomic disorders. *Cell* **131**: 1235–1247.
- Li LC, Dahiya R. 2002. MethPrimer: Designing primers for methylation PCRs. *Bioinformatics* **18**: 1427–1431.
- Lo PK, Lee JS, Liang X, Han L, Mori T, Fackler MJ, Sadik H, Argani P, Pandita TK, Sukumar S. 2010. Epigenetic inactivation of the potential tumor suppressor gene *FOXF1* in breast cancer. *Cancer Res* **70**: 6047–6058.
- Luedi PP, Dietrich FS, Weidman JR, Bosko JM, Jirtle RL, Hartemink AJ. 2007. Computational and experimental identification of novel human imprinted genes. *Genome Res* **17**: 1723–1730.
- Madison BB, McKenna LB, Dolson D, Epstein DJ, Kaestner KH. 2009. FoxF1 and FoxL1 Hedgehog signaling and the control of epithelial proliferation in the developing stomach and intestine. *J Biol Chem* **284**: 5936–5944.
- Maeda Y, Dave V, Whitsett JA. 2007. Transcriptional control of lung morphogenesis. *Physiol Rev* **87**: 219–244.
- Mahlpluu M, Enerbäck S, Carlsson P. 2001a. Haploinsufficiency of the Forkhead gene *Foxf1*, a target for Sonic hedgehog signaling, causes lung and foregut malformations. *Development* **128**: 2397–2406.
- Mahlpluu M, Ormestad M, Enerbäck S, Carlsson P. 2001b. The Forkhead transcription factor Foxf1 is required for differentiation of extra-embryonic and lateral plate mesoderm. *Development* **128**: 155–166.
- Matoušková M, Blazková J, Pajer P, Pavlíček A, Hejnar J. 2006. CpG methylation suppresses transcriptional activity of human syncytin-1 in non-placental tissues. *Exp Cell Res* **312**: 1011–1020.
- Mattick JS. 2009. The genetic signatures of noncoding RNAs. *PLoS Genet* **5**: e1000459. doi: 10.1371/journal.pgen.1000459.
- Mattick JS. 2010. Linc-ing long noncoding RNAs and enhancer function. *Dev Cell* **19**: 485–486.
- Nagano T, Fraser P. 2011. No-nonsense functions for long noncoding RNAs. *Cell* **145**: 178–181.
- Ørom UA, Derrien T, Beringer M, Gumireddy K, Gardini A, Bussotti G, Lai F, Zytznicki M, Notredame C, Huang Q, et al. 2010. Long noncoding RNAs with enhancer-like function in human cells. *Cell* **143**: 46–58.
- Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, et al. 2004. Complete sequencing and characterization of 21,243 full-length human cDNAs. *Nat Genet* **36**: 40–45.
- Phillips JE, Corces VG. 2009. CTCF: Master weaver of the genome. *Cell* **137**: 1194–1211.
- Pierrou S, Hellqvist M, Samuelsson L, Enerbäck S, Carlsson P. 1994. Cloning and characterization of seven human Forkhead proteins: Binding site specificity and DNA bending. *EMBO J* **13**: 5002–5012.
- Roessler E, Ermilov AN, Grange DK, Wang A, Grachtchouk M, Dlugosz AA, Muenke M. 2005. A previously unidentified amino-terminal domain regulates transcriptional activity of wild-type and disease-associated human GLI2. *Hum Mol Genet* **14**: 2181–2188.
- Rutter M, Wang J, Huang Z, Kuliszewski M, Post M. 2010. Gli2 influences proliferation in the developing lung through regulation of cyclin expression. *Am J Respir Cell Mol Biol* **42**: 615–625.
- Sen P, Thakur N, Stockton DW, Langston C, Bejjani BA. 2004. Expanding the phenotype of alveolar capillary dysplasia (ACD). *J Pediatr* **145**: 646–651.
- Sen P, Gerychova R, Janku P, Jezova M, Valaskova I, Navarro C, Silva I, Langston C, Welty S, Belmont J, et al. 2012. A familial case of alveolar capillary dysplasia with misalignment of pulmonary veins supports paternal imprinting of *FOXF1* in human. *Eur J Hum Genet* doi: 10.1038/ejhg.2012.171.
- Simonis M, Kooren J, de Laat W. 2007. An evaluation of 3C-based methods to capture DNA interactions. *Nat Methods* **4**: 895–901.
- Stankiewicz P, Sen P, Bhatt SS, Storer M, Xia Z, Bejjani BA, Ou Z, Wiszniewska J, Driscoll DJ, Bolivar J, et al. 2009. Genomic and genic deletions of the FOX gene cluster on 16q24.1 and inactivating mutations of *FOXF1* cause alveolar capillary dysplasia and other malformations. *Am J Hum Genet* **84**: 780–791.
- Ulitsky I, Shkumatava A, Jan CH, Sive H, Bartel DP. 2011. Conserved function of lincRNAs in vertebrate embryonic development despite rapid sequence evolution. *Cell* **147**: 1537–1550.
- Wang KC, Chang HY. 2011. Molecular mechanisms of long noncoding RNAs. *Mol Cell* **43**: 904–914.
- Winklmayr M, Schmid C, Laner-Plamberg S, Kaser A, Aberger F, Eichberger T, Frischauf A-M. 2010. Non-consensus GLI binding sites in Hedgehog target gene regulation. *BMC Mol Biol* **11**: 2. doi: 10.1186/1471-2199-11-2.
- Zhang M, Wang H, Teng H, Shi J, Zhang Y. 2010. Expression of SHH signaling pathway components in the developing human lung. *Histochem Cell Biol* **134**: 327–335.

Received April 16, 2012; accepted in revised form September 17, 2012.